ArticleOpen veterinary journal2025
Impact of Newcastle disease virus vaccines and genetic variations on interleukin-4 activation in broiler chicken.
Article in Open veterinary journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Newcastle disease virus is a virus that causes a significant economic impact on the poultry industry and is primarily controlled through vaccination. Most of the vaccinations with the LaSota strain are either live attenuated or inactivated vaccines, both of which are from the Lentogenic pathotype. Aim: This study aimed to investigate the influence of vaccine type and genetic variations on Chicken Interleukin-4 (ChIL4) activation. Methods: Three groups were examined: Group K received the killed vaccine, Group L received the live vaccine, and Group C served as the control. Blood samples were collected on days 15, 25, and 35 post-vaccinations to assess ChIL4 levels using Enzyme-Linked Immunosorbent Assay and for molecular analysis using polymerase chain reaction. Results: Group K showed a gradual increase in ChIL4 levels from 11.19 ± 0.17 to 13.70 ± 0.38, while Group L exhibited an initial increase on day 15 followed by stabilization on days 25 and 35. In contrast, ChIL4 levels in Group C declined over time from 4.84 ± 0.39 to 4.32 ± 0.25. Molecular analysis revealed four genetic variations of the single nucleotide polymorphism (SNPs) type at locations (3044, 3132, 3261, 3499) bp, with the third SNP at location (3261 bp) resulting in an amino acid change from valine to isoleucine. Analysis indicated that variants for most of these SNPs occur more likely in Group K compared to the other two groups. Conclusion: These findings suggest that genetic variations, particularly SNPs, may play a significant role in ChIL4 activation, potentially impacting vaccine efficacy and immune response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.